Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider autonomic nervous system (ANS) testing, consisting of a battery of tests in several domains (see Policy Guidelines section) to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility may be considered for autonomic nervous system (ANS) testing, consisting of a battery of tests in several domains (see Policy Guidelines section) when ALL of the following criteria are met:

- Signs and/or symptoms of autonomic dysfunction are present; AND
- A definitive diagnosis cannot be made from clinical examination and routine laboratory testing alone; AND
- Diagnosis of the suspected autonomic disorder will lead to a change in management or will eliminate the need for further testing.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers autonomic nervous system (ANS) testing to be investigational* in all other situations when criteria are not met, including but not limited to the evaluation of the following conditions:

- Chronic fatigue syndrome; OR
- Fibromyalgia; OR
- Anxiety and other psychologic disorders; OR
- Sleep apnea; OR
- Allergic conditions; OR
- Hypertension; OR
- Screening of asymptomatic individuals; OR
- Monitoring progression of disease or response to treatment.

Autonomic nervous system (ANS) testing using portable automated devices for all indications (see Policy Guidelines section) is considered to be investigational*.
Policy Guidelines

Although there is no standard battery of tests that are part of autonomic nervous system (ANS) testing, a full battery of testing generally consists of individual tests in 3 categories.

- Cardiovagal function (heart rate variability [HRV], heart rate response to deep breathing and Valsalva maneuver)
- Vasomotor adrenergic function (BP response to standing, Valsalva maneuver, and hand grip, tilt table testing)
- Sudomotor function (Quantitative Sudomotor Axon Reflex Test [QSART], quantitative sensory test, Thermoregulatory Sweat Test, silastic sweat imprint, sympathetic skin response, electrochemical sweat conductance).

At least 1 test in each category is usually performed. More than 1 test from a category will often be included in a battery of tests, but the incremental value of using multiple tests in a category is unknown.

There is little evidence on the comparative accuracy of different autonomic nervous system (ANS) tests, but the following tests are generally considered to have uncertain value in autonomic nervous system (ANS) testing:

- Pupillography
- Pupil edge light cycle
- Gastric emptying tests
- Cold pressor test
- Plasma catecholamine levels
- Skin vasomotor testing
- The ANSAR® test.

Autonomic nervous system (ANS) testing should be performed in a dedicated autonomic nervous system (ANS) testing laboratory. Testing in a dedicated laboratory should be performed under closely controlled conditions, and interpretation of the results should be performed by an individual with expertise in autonomic nervous system (ANS) testing. Testing using automated devices with interpretation of the results performed by computer software has not been validated and thus has the potential to lead to erroneous results.

Background/Overview

AUTONOMIC NERVOUS SYSTEM

The ANS has a primary role in controlling physiologic processes not generally under conscious control. They include heart rate, respirations, gastrointestinal (GI) motility, thermal regulation, bladder control, and sexual function. The ANS is a complex neural regulatory network that consists of 2 complementary systems that work to maintain homeostasis: the sympathetic and the parasympathetic systems. The sympathetic nervous system is responsible for arousal, and sympathetic stimulation leads to increased pulse, increased BP, increased sweating, decreased GI motility, and an increase on other glandular exocrine secretions.
Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

This is typically understood as the “fight or flight” response. Activation of the parasympathetic nervous system will mostly have the opposite effects; BP and pulse will decrease, GI motility increases, and there will be a decrease in sweating and other glandular secretions.

ANS DISORDERS

ANS disorders, also called dysautonomias, are heterogeneous in etiology, clinical symptoms, and severity. ANS disorders can be limited and focal, such as patients with isolated neurocardiogenic syncope or idiopathic palmar hyperhidrosis. At the other extreme, some ANS disorders can be widespread and severely disabling, such as multiple systems atrophy, which leads to widespread and severe autonomic failure. Symptoms of autonomic disorders can vary, based on the etiology and location of dysfunction. Cardiovascular manifestations are often prominent. Involvement of the cardiovascular system causes abnormalities in heart rate control and vascular dynamics. Orthostatic hypotension and other manifestations of BP lability can occur, causing weakness, dizziness, and syncope. Resting tachycardia and an inability to appropriately increase heart rate in response to exertion leads to exercise intolerance. There is a 2- to 3-fold higher incidence of major cardiac events in patients with diabetic autonomic neuropathy (myocardial infarction, heart failure, resuscitation from ventricular arrhythmia, angina, or the need for revascularization). There is also an increase in sudden cardiac death and overall mortality for these patients.

Many other organ systems can be affected by autonomic neuropathy. Involvement of the bladder can lead to incomplete emptying, resulting in urinary retention and possible overflow incontinence. GI involvement is commonly manifested as gastroparesis, which is defined as slowed gastric emptying, and can cause nausea, vomiting, and a decreased tolerance for solid food and large meals. Constipation may also occur if the lower GI tract is involved. Impairment of sexual function in males can manifest as erectile dysfunction and ejaculatory failure. Dysfunction of thermal regulation and sweating can lead to anhidrosis and heat intolerance. Paradoxically, excessive sweating can also occur as a compensatory mechanism in unaffected regions.

A classification of the different types of autonomic dysfunction, adapted from Freeman (2005) and Macdougall and McLeod (1996), can be made as follows:

- Diabetic autonomic neuropathy
- Amyloid neuropathy
- Immune-mediated neuropathy
  - Rheumatoid arthritis
  - Systemic lupus erythematosus
  - Sjögren syndrome
- Paraneoplastic neuropathy
- Inflammatory neuropathy
  - Guillain-Barré syndrome
  - Chronic inflammatory demyelinating polyneuropathy
  - Crohn disease
  - Ulcerative colitis

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hereditary autonomic neuropathies
Autonomic neuropathy secondary to infectious disease
  o HIV disease
  o Lyme disease
  o Chagas disease
  o Diphtheria
  o Leprosy
Acute and subacute idiopathic autonomic neuropathy
Toxic neuropathies.

A variety of other chronic diseases may involve an ANS imbalance, without outright dysfunction of the nerves themselves. Approximately 40% of individuals with essential hypertension will show evidence of excess sympathetic activity. Sympathetic overactivity is also a prominent feature of generalized anxiety, panic disorder, and some types of depression, as well as certain cardiac disorders such as chronic heart failure. These types of ANS imbalances are not usually classified as ANS disorders.

**Treatment**

Much of the treatment for autonomic disorders is nonpharmacologic and supportive. However, there are specific actions that can improve symptoms in patients with specific deficits. For patients with orthostatic hypotension, this involves adequate intake of fluids and salt, moving to an upright position slowly and deliberately, use of lower-extremity compression stockings, and keeping the head of the bed elevated 4 to 6 inches (10-15 cm). In severe cases, treatment with medications that promote salt retention, such as fludrocortisone, is often prescribed. Patients with symptoms of hyperhidrosis may benefit from cooling devices and potent antiperspirants such as Drysol, and patients with decreased tearing and dry mucous membranes can use over-the-counter artificial tears or other artificial moisturizers.

**ANS Testing**

ANS testing consists of a battery of tests. Any single test may be performed individually, or the entire battery of tests may be ordered. Individual components of testing may include:

- **Cardiovagal function testing**
  - Heart rate variability. Beat-to-beat variability in the heart rate can be measured at rest, or in response to provocative measures, such as deep breathing or the Valsalva maneuver. Reduced, or absent, HRV is a sign of autonomic dysfunction.
  - Baroreflex sensitivity. Baroreflex sensitivity is measured by examining the change in pulse and HRV in response to changes in BP. A medication such as phenylephrine is given to induce a raise in BP, and baroreflex sensitivity is calculated as the slope of the relation between HRV and BP.

- **Sudomotor function (sweat testing).** Sweat testing evaluates the structure and function of nerves that regulate the sweat glands.
  - QSART test. The QSART is an example of a commercially available semiquantitative test of sudomotor function. The test is performed by placing color-sensitive paper on the skin,
which changes color on contact with sweat. Measurement of the amount of color change is a semiquantitative measure of sudomotor function.

- **Silastic sweat imprint.** For the silastic sweat imprint, silastic material is placed on the skin, and the sweat droplets form indentations on the silastic surface, allowing quantitation of the degree of sweating present. The Neuropad test is an example of a commercially available silastic sweat imprint.

- **Thermoregulatory Sweat Test.** A more complex approach in some centers is the use of a thermoregulatory laboratory. This is a closed chamber in which an individual sits for a defined period of time under tightly controlled temperature and humidity. An indicator dye is brushed on the skin, and it changes color when in contact with sweat. Digital pictures are taken and projected onto anatomic diagrams. Computer processing derives values for total area of anhidrosis and the percent of anhidrotic areas.

- **Sympathetic skin response.** Sympathetic skin response tests use an electric current to stimulate sympathetic nerves. The tests measure the change in electrical resistance, which is altered in the presence of sweat. In general, these tests are considered to be sensitive, but have high variability and potential for false-positive results. A variant of sympathetic skin response testing is electrochemical sweat conductance measured by iontophoresis (e.g., Sudoscan). In this test, a low-level current is used to attract chloride ions from sweat glands. The chloride ions interact with stainless-steel plate electrodes to measure electrochemical resistance.

- **Salivation testing.** The protocol for salivation testing involves the subject chewing on a preweighed gauze for 5 minutes. At the end of 5 minutes, the gauze is removed and reweighed to determine the total weight of saliva present.

- **Tilt table testing.** Tilt table testing is intended to evaluate for orthostatic intolerance. The patient lies on the table and is strapped in with a foot rest. The table is then inclined to the upright position, with monitoring of the pulse and BP. Symptoms of lightheadedness or syncope in conjunction with changes in pulse or BP constitute a positive test. A provocative medication, such as isoproterenol, can be given to increase the sensitivity of the test.

**Composite Autonomic Severity Score**

The Composite Autonomic Severity Score, which ranges from 0 to 10, is intended to estimate severity of autonomic dysfunction. Scores are based on self-reported symptoms measured by a standardized symptom survey. Scores of 3 or less are considered mild, scores of 3 to 7 are considered moderate, and scores greater than 7 are considered severe.

**FDA or Other Governmental Regulatory Approval**

U.S. Food and Drug Administration (FDA)

Since 1976, numerous ANS testing devices have been cleared for marketing by the US FDA through the 510(k) process. Table 1 lists examples.
Autonomic Nervous System Testing

Policy #: 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

Table 1. Autonomic Nervous System Test Devices

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Measurement</th>
<th>510(k) No.</th>
<th>Clearance Date</th>
<th>FDA Product Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANX 3.0</td>
<td>Ansar Group</td>
<td>Respiration and heart rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>variability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudoscan</td>
<td>Impeto Medical</td>
<td>Electrochemical sweat conductance</td>
<td>K10023</td>
<td>2010</td>
<td>GZO</td>
</tr>
<tr>
<td>ZYTO Hand</td>
<td>ZYTO Technologies</td>
<td>Galvanic skin response</td>
<td>K11130</td>
<td>2011</td>
<td>GZO</td>
</tr>
<tr>
<td>Bodytronic</td>
<td>Bauerfeind</td>
<td>Photoelectric plethysmograph</td>
<td>K12392</td>
<td>2013</td>
<td>JMO</td>
</tr>
<tr>
<td>Neupad</td>
<td>TRIGOcare</td>
<td>Sudomotor function</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration.

Centers for Medicare and Medicaid Services (CMS)
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

**Rationale/Source**
Assessment of a diagnostic technology typically focuses on 3 categories of evidence: (1) technical performance (test-retest reliability or interrater reliability); (2) diagnostic accuracy (sensitivity, specificity, and positive and negative predictive value) in relevant populations of patients; and (3) demonstration that the diagnostic information can be used to improve patient outcomes (clinical utility).

**AUTONOMIC NERVOUS SYSTEM TESTING**
**Clinical Context and Test Purpose**
The purpose of ANS testing in patients who have signs and/or symptoms of ANS dysfunction is to aid in the diagnosis of disease and guide treatment.
The question addressed in this evidence review is: Does the evidence indicate that ANS testing improves health outcomes in patients who have signs and/or symptoms of ANS without a definitive diagnosis.

The following PICOTS were used to select literature to inform this review.

**Patients**
The relevant population of interest is patients who have signs and/or symptoms of ANS without a definitive diagnosis.

**Interventions**
ANS testing is performed to evaluate the integrity and function of the ANS. Although there is no standard battery of tests for ANS testing, a full battery generally consists of individual tests in 3 domains.
- Cardiovagal function (HRV, heart rate response to deep breathing and Valsalva maneuver)
Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

- Vasomotor adrenergic function (BP response to standing, Valsalva maneuver, and hand grip, tilt table testing)
- Sudomotor function (QSART, quantitative sensory testing [QST], Thermoregulatory Sweat Test [TST], silastic sweat imprint, sympathetic skin response, electrochemical sweat conductance).

Comparators
The following tools, tests, rules, and practices are currently used to make decisions about the diagnosis signs and/or symptoms of ANS: standard clinical diagnostic workup without ANS testing.

Outcomes
The outcomes of interest for technical performance are test-retest reliability or interrater reliability. The relevant outcomes for diagnostic accuracy are sensitivity, specificity, predictive values, and related measures of diagnostic accuracy. The outcomes for clinical validity include aiding in diagnosis of disease and guiding management. Much of the treatment for autonomic disorders is nonpharmacologic and supportive, but there are specific actions that can improve symptoms in patients with specific deficits and improve quality of life.

Timing
ANS tests are typically performed following clinical evaluation to confirm a diagnosis or to provide additional information for diagnosis.

Setting
ANS testing should be performed in a dedicated ANS testing laboratory. Interpretation of the results should be performed by an individual with expertise in ANS testing.

Technical Performance
ANS testing is essentially the only laboratory method available to evaluate ANS dysfunction. Because of the lack of a true criterion standard of autonomic dysfunction, the validity of results of ANS testing cannot be determined.

Some evidence was identified on the reliability of ANS testing, particularly for HRV. A number of studies have reported that the test-retest reliability of ANS is high over short periods of time, but reliability over longer time periods is less certain. A systematic review of published studies on the reliability of HRV was published in 2005. Reviewers identified 8 studies (total N=183 patients) that reported on the reliability of short-term recordings (i.e., excluding studies that used 24-hour monitoring). Four studies included healthy patients, 3 included patients with cardiac disease, and one included both healthy and cardiac patients. Studies used different measures of HRV, and reviewers performed a qualitative synthesis of the results. For 3 of the 5 studies that included healthy individuals, the reliability was high, with coefficients of variation (CVs) ranging from 6% to 15%. However, in the other 2 studies, the CV was much higher at 20% in one and 45% in the other. For patients with cardiac disease, the reliability was lower, with CVs being higher and reaching 100% in 1 study.
Less evidence was available for other specific tests. For sudomotor testing, 2 small studies assessing reliability were identified. Berger et al (2013) evaluated the reliability of the QSART in 20 healthy individuals. They reported intraclass correlation coefficients (ICCs) at 3 different body sites ranging from 0.49 to 0.75, indicating moderate reliability, and standard error of measurements ranging from 0.273 to 0.978, indicating large standard errors. Peltier et al (2009) evaluated both the QSART and QST in 23 patients with impaired glucose regulation and neuropathy. The ICCs were high for both measures, ranging from 0.52 to 0.80. QST was more reliable (ICC range, 0.75-0.80) than the QSART (ICC=0.52), indicating suboptimal reliability.

Some studies have evaluated the reproducibility of tilt testing, usually by repeating a study in patients with an initial positive test. An example of this type of study was published by Kouchadakis et al in 1998. It evaluated 35 patients with syncope and a positive tilt table test using a repeat tilt table test. The study also included a comparison group (15 healthy volunteers) that underwent 2 tilt table tests. In conjunction with tilt table testing, the study also recorded HRV. Twenty-one (60%) of the 35 patients had a second positive test, while none of the healthy controls had any positive test. HRV results showed that high parasympathetic predicted a second positive test.

**Section Summary: Technical Performance**

The main evidence on the technical performance of ANS testing is on the reliability of individual tests, mostly test-retest reproducibility. The available evidence is incomplete, and there is a lack of high-quality reporting on reliability. The available research is variable and, in most cases, does not show high reproducibility. Therefore, the reliability of these tests is currently uncertain.

**Diagnostic Accuracy**

There are a number of challenges when evaluating the diagnostic accuracy of ANS testing:

- There is a lack of a true criterion standard for determining autonomic dysfunction. Comparisons with imperfect criterion standards, such as clinical examination or nerve conduction studies, may lead to biased estimates of accuracy.
- Most of the ANS is inaccessible to testing, and available tests are measures of end-organ response rather than direct measures of ANS function.
- There are numerous individual tests of ANS function, and a combination of them is typically used in ANS testing. Diagnostic accuracy could be reported for each individual test or for the package of testing performed.
- Different types of equipment may be used for testing, and the accuracy of different systems may vary.

Scattered reports of diagnostic accuracy for specific tests in specific patient groups are available, but high-quality research is lacking. The most rigorous evaluation of diagnostic accuracy identified was in the systematic review by the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation, which focused on the accuracy of autonomic testing for distal symmetric polyneuropathy. Table 2 summarizes the results on diagnostic accuracy from this review. While reported sensitivities and specificities are high, the populations in these studies include patients with known disease and healthy volunteers. These populations...
Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

are not optimal for determining diagnostic accuracy, and are known to lead to inflated estimates of both sensitivity and specificity.

<table>
<thead>
<tr>
<th>Study/Year</th>
<th>Disorder Studied</th>
<th>Test(s) Used</th>
<th>Reference Standard</th>
<th>N</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart (1992)</td>
<td>DSFN</td>
<td>HRV, QST, QSART</td>
<td>Clinical exam</td>
<td>16</td>
<td>80%</td>
<td>72%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EDx studies</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyck (1992)</td>
<td>Diabetic polyneuropathy</td>
<td>QAE</td>
<td>EDx studies</td>
<td>73</td>
<td>97%</td>
<td>&gt;90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (1997)</td>
<td>Parkinson, multisystem atrophy</td>
<td>QSART</td>
<td>Older scale for autonomic neuropathy</td>
<td>57</td>
<td>&gt;90%</td>
<td>&gt;90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobin (1999)</td>
<td>DSFN</td>
<td>Clinical sx, QSART, QST</td>
<td>EDx studies</td>
<td>49</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>80% (QSART)</td>
<td>93%</td>
</tr>
<tr>
<td>Novak (2001)</td>
<td>Painful neuropathy</td>
<td>QSART, ART</td>
<td>Clinical exam</td>
<td>48</td>
<td>93% (ART)</td>
<td>94%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CASS</td>
<td></td>
<td>3</td>
<td>73% (QSART)</td>
<td></td>
</tr>
<tr>
<td>Low (1993)</td>
<td>Diabetic polyneuropathy</td>
<td>CASS</td>
<td>Clinical exam</td>
<td>42</td>
<td>&gt;90%</td>
<td>&gt;90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EDx studies</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schrezenmaier (2007)</td>
<td>Adrenergic failure</td>
<td>BRSI</td>
<td>MSNA</td>
<td>11</td>
<td>86%</td>
<td>&gt;90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vogel (2005)</td>
<td>Polyneuropathy, multisystem atrophy</td>
<td>PRT, CASS</td>
<td>Clinical exam</td>
<td>19</td>
<td>&gt;90%</td>
<td>&gt;90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singer (2004)</td>
<td>DSFN, diabetic and idiopathic neuropathy</td>
<td>CASS</td>
<td>Neurologic exam</td>
<td>49</td>
<td>95%</td>
<td>90%</td>
</tr>
</tbody>
</table>

ART: autonomic reflex testing; BRSI: baroreflex sensitivity index; CASS: Composite Autonomic Severity Score; DSFN: distal small fiber neuropathy; EDx: electrodiagnostic studies (electromyography/nerve conduction velocity); HRV: heart rate variability; MSNA: muscle sympathetic nerve activity; PRT: blood pressure recovery time; QAE: quantitative autonomic evaluation; QSART: Quantitative Sudomotor Axon Reflex Test; QST: quantitative sensory testing; sx: symptoms.

In 2016, da Silva et al reported on a systematic review of the accuracy of HRV for the diagnosis and prognosis of cardiac autonomic neuropathy in individuals with diabetes. Reviewers included 8 studies, finding that HRV is useful to discriminate cardiac autonomic neuropathy. Measures of sample entropy, SD1/SD2 indices (standard deviation of the instantaneous variability and long-term variability), SDANN (standard deviation of mean of normal relative risk intervals every 5 minutes for a period of time, expressed in milliseconds), high frequency component, and slope of heart rate turbulence had the best discriminatory power, with sensitivity ranging from 72% to 100% and specificity ranging from 71% to 97%.
Evidence on the sensitivity and specificity of a silastic sweat testing device (Neuropad) was identified. Kamenov et al (2010) enrolled 264 inpatients with diabetes. Patients with autonomic neuropathy were identified by the Neuropathy Disability Score, with a cutoff of 5 indicating autonomic neuropathy. An abnormal silastic sweat test had a sensitivity of 76%, a specificity of 56%, a positive predictive value of 86%, and a negative predictive value of 40%. In a similar study, Quattrini et al (2008) evaluated 57 diabetic patients with several autonomic tests, including the Neuropad device. The sensitivity of silastic sweat testing in this study was 85%, the specificity was 45%, the positive predictive value was 69%, and the negative predictive value was 71%.

Another diagnostic accuracy study of the Neuropad device was published in 2014. It included 38 patients with diabetic peripheral neuropathy and 89 patients without neuropathy. The diagnostic performance of Neuropad was compared with a number of other measures of nerve function. Compared with other measures of large fiber dysfunction, the Neuropad had a sensitivity ranging from 70% to 83% and a specificity ranging from 50% to 54%. Compared with a measure of small fiber function (corneal nerve fiber length), the sensitivity was 83% and the specificity was 80%.

In 2013, Casselini et al compared the accuracy of the Sudoscan test with other available tests of sudomotor function. This study evaluated 83 patients with diabetes (60 with peripheral neuropathy, 20 without peripheral neuropathy) and 210 normal controls. Electrochemical skin conductance of the feet was lowest for patients with diabetes and neuropathy (56.3, SEM=3), intermediate for patients with diabetes without neuropathy (75.9, SEM=5.5), and highest for normal volunteers (84.4, SEM=0.9, p<0.001 for group differences). Using clinically defined neuropathy as the criterion standard, sensitivity was 78% and specificity was 92%. Results of the test correlated significantly with a number of other measures, including symptom scores, QST, and measures of HRV. The correlations were in the low-to-moderate range (Spearman \( \rho \) range, 0.24-0.47).

**Section Summary: Diagnostic Accuracy**

It is not possible to determine the diagnostic accuracy of ANS testing. The lack of a criterion standard makes it difficult to perform high-quality research in this area. The available research has reported sensitivity in patients with clinically defined disease and specificity in health volunteers. This type of study design is known to produce inflated estimates of sensitivity and specificity; therefore, the diagnostic accuracy of testing in clinical practice is uncertain.

**Clinical Utility**

The use of ANS testing will improve outcomes if the test has incremental diagnostic accuracy over clinical exam alone, and if establishing the diagnosis leads to changes in management that improves outcomes. There is a lack of direct evidence on the impact of ANS testing on changes in management or health outcomes. It is likely that these tests provide information beyond that obtainable from the clinical exam alone, given the limitations of physical exam for assessing physiologic processes. Some autonomic disorders have specific treatments, such as medications to retain salt and preserve hydration status. In other cases, the use of autonomic testing may limit the need for further diagnostic testing, when symptoms
are possibly autonomic related, but may be due to other pathology. In those cases, determining whether autonomic dysfunction is the cause of symptoms may end the need for further testing.

**SUMMARY OF EVIDENCE**

For individuals who have signs and symptoms of ANS dysfunction who receive ANS testing, the evidence includes studies of diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, functional outcomes, and quality of life. The evidence base is limited. There is a lack of a criterion standard for determining autonomic dysfunction, which limits the ability to perform high-quality research on diagnostic accuracy. Also, numerous tests are used in various conditions, making it difficult to determine values for overall diagnostic accuracy of a battery of tests. The evidence on the reliability of individual tests raises concerns about the reproducibility of testing. Scattered reports of diagnostic accuracy are available for certain tests, most commonly in the diabetic population, but these reports do not specify estimates of accuracy for the entire battery of tests. Reported sensitivities and specificities are high for patients with clinically defined distal symmetric polyneuropathy using a symptom-based score as a reference standard, but these estimates are likely biased by study designs that use patients with clinically diagnosed disease and a control group of healthy volunteers. Among the few clinical practice guidelines from specialty societies, recommendations are primarily based on expert opinion. The evidence is insufficient to determine the effects of the technology on health outcomes.

**References**

Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017


Policy History

Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

11/02/2017 Medical Policy Committee review

Next Scheduled Review Date: 11/2018

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Autonomic Nervous System Testing

Policy # 00591
Original Effective Date: 11/15/2017
Current Effective Date: 11/15/2017

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>95921, 95922, 95923, 95924, 95943</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses codes</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”)- Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury, disease or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.